Subtopic Deep Dive
Small Cell Lung Cancer Genomic Profiles
Research Guide
What is Small Cell Lung Cancer Genomic Profiles?
Small Cell Lung Cancer Genomic Profiles refer to the comprehensive molecular characterization of genetic alterations, including recurrent mutations in TP53, RB1, and NOTCH family genes, revealed by next-generation sequencing in SCLC tumors.
Next-generation sequencing studies identify TP53 and RB1 inactivation in nearly all SCLC cases alongside NOTCH pathway disruptions driving tumor heterogeneity (George et al., 2015; 2284 citations). Integrative analyses confirm these as key somatic drivers with tobacco exposure signatures (Peifer et al., 2012; 1398 citations). Over 10 major genomic profiling papers exist since 2009.
Why It Matters
Genomic profiles of SCLC reveal therapeutic vulnerabilities like DLL3 expression for targeted therapies and immunotherapy responses tracked in trials (Horn et al., 2018; 3325 citations). These profiles enable precision medicine by identifying mutation-based subtypes resistant to standard chemotherapy (Rudin et al., 2021; 1401 citations). Peifer et al. (2012) data supports biomarker development for early detection amid SCLC's rapid progression and 5-year survival below 7%.
Key Research Challenges
Intratumor Heterogeneity
SCLC exhibits high genomic instability with evolving subclones under therapy, complicating targeted treatments (George et al., 2015). Peifer et al. (2012) identified variable NOTCH mutations across samples, hindering uniform profiling. Longitudinal sequencing is needed to track evolution.
Limited Tissue Availability
SCLC's aggressive nature and small biopsy sizes limit comprehensive NGS profiling (Rudin et al., 2021). Pleasance et al. (2009; 1055 citations) relied on rare samples, underscoring biopsy challenges. Liquid biopsy methods remain underdeveloped for SCLC.
Translational Biomarker Gaps
Driver mutations like TP53/RB1 lack direct therapies despite prevalence (George et al., 2015). Horn et al. (2018) showed immunotherapy benefits without genomic predictors. Bridging profiles to clinical outcomes requires validation cohorts.
Essential Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · 2018 · New England Journal of Medicine · 3.3K citations
The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival th...
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · 2016 · Annals of Oncology · 2.6K citations
Comprehensive genomic profiles of small cell lung cancer
Julie George, Jing Lim, Se Jin Jang et al. · 2015 · Nature · 2.3K citations
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin, Salman M. Toor, Varun Sasidharan Nair et al. · 2018 · Experimental & Molecular Medicine · 2.1K citations
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa, Shaker A. Mousa · 2016 · Translational Lung Cancer Research · 1.9K citations
Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung cancer (NSCLC) accoun...
Reading Guide
Foundational Papers
Start with Peifer et al. (2012; Nature Genetics) for core driver mutations (TP53, RB1), then George et al. (2015; Nature) for comprehensive profiles, and Pleasance et al. (2009) for tobacco signatures establishing early genomic evidence.
Recent Advances
Rudin et al. (2021; Nature Reviews Disease Primers, 1401 citations) integrates profiles with therapy; Horn et al. (2018) links to immunotherapy outcomes.
Core Methods
Whole-exome/whole-genome sequencing for SNVs/CNA; RNA-seq for expression subtypes (SCLC-A to -N); integrative multi-omics from Peifer et al. (2012) and George et al. (2015).
How PapersFlow Helps You Research Small Cell Lung Cancer Genomic Profiles
Discover & Search
Research Agent uses searchPapers and citationGraph to map SCLC genomics from George et al. (2015), revealing 2284 citations and clusters around TP53/RB1. exaSearch uncovers tobacco signature links from Pleasance et al. (2009), while findSimilarPapers expands to Peifer et al. (2012).
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation frequencies from George et al. (2015), then runPythonAnalysis for statistical verification of TP53 prevalence (95%+ cases) using pandas. verifyResponse with CoVe and GRADE grading ensures claims match Rudin et al. (2021) evidence levels.
Synthesize & Write
Synthesis Agent detects gaps in NOTCH targeting post George et al. (2015), flagging contradictions with Peifer et al. (2012). Writing Agent uses latexEditText, latexSyncCitations for SCLC subtype tables, and latexCompile for manuscripts with exportMermaid genomic pathway diagrams.
Use Cases
"Analyze mutation frequencies across SCLC genomic papers with statistics."
Research Agent → searchPapers('SCLC TP53 RB1') → Analysis Agent → readPaperContent(George 2015) → runPythonAnalysis(pandas aggregation of mutation rates) → CSV export of prevalence table (TP53: 95%, RB1: 93%).
"Draft a review section on SCLC drivers with citations and figure."
Synthesis Agent → gap detection(TP53 therapies) → Writing Agent → latexEditText('SCLC Genomic Drivers') → latexSyncCitations(Peifer 2012, George 2015) → latexCompile → PDF with Mermaid mutation network diagram.
"Find code for SCLC genomic analysis from related repos."
Research Agent → paperExtractUrls(Pleasance 2009) → paperFindGithubRepo(tobacco mutation signatures) → githubRepoInspect → Code Discovery workflow outputs NGS pipeline scripts for variant calling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ SCLC papers: searchPapers → citationGraph(George 2015 hub) → structured report on subtype evolution. DeepScan applies 7-step analysis with CoVe checkpoints to verify RB1 inactivation rates from Peifer et al. (2012). Theorizer generates hypotheses on NOTCH restoration therapies from genomic profiles.
Frequently Asked Questions
What defines Small Cell Lung Cancer Genomic Profiles?
Comprehensive NGS-based maps of mutations, with TP53 and RB1 inactivated in 90-100% of cases and NOTCH alterations in subsets (George et al., 2015).
What are key methods in SCLC genomic profiling?
Whole-exome sequencing and integrative analyses detect drivers like TP53/RB1 biallelic loss; RNA-seq reveals subtypes (Peifer et al., 2012; George et al., 2015).
What are landmark papers?
George et al. (2015; Nature, 2284 citations) provides comprehensive profiles; Peifer et al. (2012; Nature Genetics, 1398 citations) identifies drivers; Rudin et al. (2021) reviews clinical translation.
What open problems exist?
Developing therapies for universal TP53/RB1 mutations; resolving intratumor heterogeneity; validating liquid biopsies for profiling (Rudin et al., 2021).
Research Lung Cancer Research Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Small Cell Lung Cancer Genomic Profiles with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lung Cancer Research Studies Research Guide